Prof Vera Bittner (University of Alabama at Brimingham, Birmingham, AL,US) discusses the ODYSSEY OUTCOMES Trial - Lipoprotein(a) lowering by alirocumab contributes to total events reduction independent of LDL cholesterol.

Filmed on site at ACC 2019 by Radcliffe Cardiology

Questions:

1. Please remind us of the ODYSSEY trial and its key findings?

2. What was the rationale for this sub-analysis and how was it conducted?

3. What does this mean for clinical practice?

4. What else should be anticipated from the ODSYSEY programme?

Videography: Josh Birch

Interviewer: Liam O’Neill